Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07454915) titled 'PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia' on Feb. 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: PapiVax Biotech, Inc.
Condition:
Cervical Intraepithelial Neoplasia Grade 2/3
Human Papilloma Virus Infection Type 16
Intervention:
Combination Product: PVX4 Combination Product
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 1, 2026
Target Sample Size: ...